NURO NeuroMetrix Corp: Bathi saben saham sajrone 12 wulan pungkasan

NeuroMetrix, Inc. (NURO) develops non-pharmacological devices to combat chronic pain, eliminating patient chemical dependency. The EPS YoY TTM growth trajectory reflects profit dynamics, with the latest figure standing at -2.10. The business relies on the sale of disposable electrodes, ensuring recurring revenue. Currently, NeuroMetrix, Inc. (NURO) is focusing on expanding insurance reimbursements for its mature neuropathy diagnostic products.
Rincian metrik keuangan lan pasar NeuroMetrix Corporation (NURO)

The effectiveness of the Quell technology implementation correlates directly with the rolling earnings per share (EPS) YoY trend. This metric measures the percentage growth of net income over the last 12 months relative to the same period last year. The calculation logic reveals the actual speed of business recovery and the sustainability of cash generation. Stable clinic demand for NeuroMetrix, Inc. (NURO) devices ensures high margins, as reflected in this indicator. The positive trend confirms the fundamental value of the assets and the reliability of the operating model.